BALTIMORE, May 17, 2018 /PRNewswire-USNewswire/
-- Today, the American Urological Association (AUA), a leading
global urology association, announced updates to its
Castration-Resistant Prostate Cancer (CRPC) clinical guideline, to
incorporate new published research related to the treatment of
patients with non-metastatic CRPC.
Clinicians are challenged with a multitude of treatment options
for patients with CRPC, which is the progression of prostate cancer
despite castrate levels of androgens. To assist physicians with
clinical decision-making, the AUA first released guideline
statements in 2013 targeting six index patients representing the
most common scenarios encountered in clinical practice. With these
patients in mind, guideline statements were developed to provide a
rational basis for treatment. The 2018 amendment reflects the
latest research regarding treatment of patients with asymptomatic
non-metastatic CRPC, one of the represented index patients in the
2013 guideline.
"Emerging targeted therapies for non-metastatic CRPC continue to
surface, and it's important to regularly incorporate the new
evidence-based therapies into AUA's clinical guideline that doctors
routinely use," says Michael
Cookson, MD, chair of the original 2013 guideline panel and
member of the 2018 amendment panel. "We are confident this
guideline is fully aligned with the latest science on treatments
for patients with non-metastatic and metastatic
CRPC."
The Castration-Resistant Prostate Cancer: AUA Guideline
was amended as follows:
- Guideline Statement 1 was added to incorporate two therapies
that have shown benefit in this patient population: apalutamide, a
nonsteroidal anti-androgen, which in 2018 became the first
FDA-approved treatment for patients with non-metastatic disease;
and enzalutamide, an androgen receptor signaling inhibitor, which
has shown benefit in metastatic patients.
-
- Statement 1: Clinicians should offer apalutamide or
enzalutamide with continued androgen deprivation to patients with
non-metastatic CRPC at high risk for developing metastatic disease.
(Standard; Evidence Level Grade A [apalutamide] / B
[enzalutamide])
The amendment features additional supporting text and further
discussions of ongoing research. The full text of the amended
evidence-based CRPC guideline is now available online at
www.auanet.org/CRPC.
Members of the CRPC guideline panel include: Michael S. Cookson, Bruce J. Roth, Philipp
Dahm, Christine Engstrom,
Stephen J. Freedland, Maha Hussain,
Daniel W. Lin, William T. Lowrance, Mohammad Hassan Murad, William K. Oh, David F.
Penson and Adam S. Kibel.
Additional amendment panel members include David F. Jarrard and Matthew J. Resnick.
All AUA clinical practice guidance documents, including
guidelines, best practices and white papers, are available online
at www.auanet.org/guidelines.
About the American Urological Association:
Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological
Association is a leading advocate for the specialty of urology, and
has more than 21,000 members throughout the world. The AUA is a
premier urologic association, providing invaluable support to the
urologic community as it pursues its mission of fostering the
highest standards of urologic care through education, research and
the formulation of health policy.
Contact: Christine Frey,
AUA
443-909-0839, cfrey@AUAnet.org
View original content with
multimedia:http://www.prnewswire.com/news-releases/aua-releases-updates-to-clinical-guideline-on-castration-resistant-prostate-cancer-300650271.html
SOURCE American Urological Association